THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 83 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2015. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $121 | -14.8% | 14,069 | +2.5% | 0.00% | 0.0% |
| Q2 2023 | $142 | -16.0% | 13,723 | -11.8% | 0.00% | 0.0% |
| Q1 2023 | $169 | -99.8% | 15,565 | +35.1% | 0.00% | 0.0% |
| Q1 2022 | $110,000 | -4.3% | 11,525 | +10.6% | 0.00% | 0.0% |
| Q4 2021 | $115,000 | -50.6% | 10,423 | +8.6% | 0.00% | -50.0% |
| Q1 2018 | $233,000 | -44.0% | 9,599 | -35.7% | 0.00% | -33.3% |
| Q4 2017 | $416,000 | +274.8% | 14,931 | +205.5% | 0.00% | +200.0% |
| Q2 2016 | $111,000 | +68.2% | 4,887 | +40.2% | 0.00% | – |
| Q1 2016 | $66,000 | +73.7% | 3,486 | +51.3% | 0.00% | – |
| Q4 2015 | $38,000 | +11.8% | 2,304 | -25.9% | 0.00% | – |
| Q3 2015 | $34,000 | +183.3% | 3,108 | +229.2% | 0.00% | – |
| Q2 2015 | $12,000 | -7.7% | 944 | +28.8% | 0.00% | – |
| Q1 2015 | $13,000 | +18.2% | 733 | +0.5% | 0.00% | – |
| Q4 2014 | $11,000 | -45.0% | 729 | -16.0% | 0.00% | – |
| Q3 2014 | $20,000 | -28.6% | 868 | 0.0% | 0.00% | – |
| Q2 2014 | $28,000 | – | 868 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Madison Avenue Partners, LP | 7,012,226 | $78,677,176 | 13.94% |
| Irenic Capital Management LP | 1,700,937 | $19,084,513 | 9.15% |
| Weiss Asset Management LP | 7,457,060 | $83,668,213 | 3.41% |
| Newtyn Management, LLC | 1,450,000 | $16,269,000 | 3.36% |
| Palliser Capital (UK) Ltd | 97,100 | $1,089,462 | 2.65% |
| Chescapmanager LLC | 850,988 | $9,548 | 2.24% |
| Park West Asset Management LLC | 1,920,324 | $21,546,035 | 2.11% |
| Baupost Group | 11,419,226 | $128,124 | 2.09% |
| Saturn V Capital Management LP | 141,339 | $1,334,342 | 1.11% |
| Oasis Management Co Ltd. | 296,960 | $3,331,891 | 0.66% |